Mobile
Search
Advanced search
Multi-criteria search
Who are we ?
Log in
Sign up
Français
English
Kusajili – Clinical trials directory
Result
of your search per sponsor: Amgen
Woman and Man Max 99 years
Amgen, Inc
Update Il y a 4 ans
Pembrolizumab With or Without Talimogene Laherparepvec in Squamous Cell Carcinoma of the Head and Neck Pembrolizumab con o sin Talimogene Laherparepvec en Carcinoma de Células Escamosas de Cabeza y Cuello
Phase 1b: To evaluate the safety, as assessed by incidence of dose limiting toxicity (DLT), of talimogene laherparepvec in combination with pembrolizumab in subjects with SCCHN. Phase 3: To evaluate...
Country
None
organs
None
Specialty
None
unknown
More information
Woman and Man
Between 18 years
and 99 years
Amgen
Update Il y a 7 ans
Étude 20130232 : étude de phase 1-3, randomisée, évaluant la tolérance et l’efficacité de l’association du Talimogene Laherparepvec et du Pembrolizumab chez des patients ayant un cancer de la tête et du cou récidivant ou métastatique. [Informations issues du site clinicaltrials.gov et traduites par l'INCa]
20130232 : Étude de phase 1b/3, multicentrique, randomisée, en ouvert, évaluant l’association du TVEC et du Pembrolizumab chez des patients présentant un carcinome épidermoïde de la tête et du cou réc...
Country
France
organs
Tête et cou
Specialty
Immunothérapie - Vaccinothérapie
Essai ouvert aux inclusions
More information
Woman and Man Max 99 years
Amgen, Inc
Update Il y a 4 ans
Study to Evaluate Darbepoetin alfa in Pediatric Subjects With Anemia Due to Chronic Kidney Disease
To evaluate the safety and tolerability of darbepoetin alfa following single 1.5 microgram/kg subcutaneous (SC) dose administration in paediatric subjects < 1 year of age with anaemia due to chronic k...
Country
None
organs
None
Specialty
None
unknown
More information
Woman and Man Max 99 years
Amgen, Inc
Update Il y a 4 ans
Darbepoetin alfa in Anaemic Subjects With Low Risk Myelodysplastic Syndromes - Companion Study
To provide required access of investigational product (darbepoetin alfa) beyond the end of active treatment period of the Darbepoetin alfa MDS 20090160 study for subjects that have continued demonstra...
Country
None
organs
None
Specialty
None
Closed trial
More information
Woman and Man Max 99 years
Amgen Limited
Update Il y a 4 ans
A Study to Evaluate the Efficacy of Converting from Intravenous or Subcutaneous rHuEPO to Intravenous Darbepoetin Alfa (Aranesp®) in Subjects with Chronic Kidney Disease Receiving Haemodialysis
To demonstrate that switching HD subjects with a baseline haemoglobin (Hb) ≥ 10 g/dL and ≤ 13 g/dL from either subcutaneous (SC) or intravenous (IV) rHuEPO to IV darbepoetin alfa results in a mean Hb ...
Country
None
organs
None
Specialty
None
Closed trial
More information
Woman and Man Max 99 years
Amgen, Inc
Update Il y a 4 ans
An Open Label, Sequential Cohort, Dose Escalation Study to Evaluate the Safety and Efficacy of AMG 531 in Thrombocytopenic Subjects with Low or Intermediate-1 Risk Myelodysplastic Syndrome (MDS)
To evaluate the safety and tolerability of AMG 531 in thrombocytopenic subjects with low or Intermediate-1 risk MDS.
Country
None
organs
None
Specialty
None
Closed trial
More information
Woman and Man Max 99 years
Amgen, Inc
Update Il y a 4 ans
A Randomised, Multi-Center, Double-Blind, Placebo-Controlled, Dose-Finding Study of AMG 114 Administered by Subcutaneous Injection for the Treatment of Anemia in Subjects With Non-myeloid Malignancies Receiving Multicycle Chemotherapy
To evaluate the safety, tolerability and pharmacokinetics (PK) of AMG 114 administered subcutaneously for the treatment of chemotherapy induced anemia in subjects receiving multicycle chemotherapy
Country
None
organs
None
Specialty
None
Closed trial
More information
Woman and Man Max 99 years
Amgen, Inc
Update Il y a 4 ans
A Randomized, Phase 1b/2 Trial of AMG 102 or AMG 479 in Combination with Panitumumab versus Panitumumab Alone in Subjects with Wild-Type KRAS Metastatic Colorectal Cancer. ---------------------------------------------------------------------------------------------------- Ensayo aleatorizado de fase 1b/2 de AMG 102 o AMG 479 en combinación con panitumumab frente a panitumumab en monoterapia en sujetos con cáncer colorrectal metastásico con KRAS no mutado
Part 1: To identify a tolerable dose of AMG 102 in combination with panitumumab based on the incidence of dose-limiting toxicities (DLTs) Part 2: To evaluate the efficacy as assessed by the overal...
Country
None
organs
None
Specialty
None
Closed trial
More information
Woman and Man
Between 18 years
and 99 years
Amgen
Update Il y a 4 ans
Amgen 20050159 : Essai de phase 2 d’escalade de doses évaluant l’efficacité et la tolérance du romiplostim, chez des patients thrombocytopéniques ayant un risque faible ou intermédiaire-1 de syndrome myélodisplastique (SMD). [Informations issues du site clinicaltrials.gov et traduites par l'INCa] [essai clos aux inclusions]
An open label, sequential, dose escalation study to evaluate thesafety and efficacy of Romiplostim in thrombocytopenic subjects with low or intermediate-1 risk myelodysplastic syndrome (MDS).
Country
France
organs
Sang Hématologie - Autres
Specialty
Chimiothérapie
Essai clos aux inclusions
More information
Woman and Man Max 99 years
Amgen, Inc
Update Il y a 4 ans
Study to Evaluate the Safety and Efficacy of IV Infusion Treatment With Omecamtiv Mecarbil in Subjects With Left Ventricular Systolic Dysfunction Hospitalized for Acute Heart Failure
The primary objective of the study is to evaluate the effect of 48 hours of intravenous (IV) omecamtiv mecarbil compared with placebo on dyspnea in subjects with left ventricular systolic dysfunction ...
Country
None
organs
None
Specialty
None
unknown
More information
Previous
1
2
3
4
5
6
7
8
9
10
Next